Cambrex adding $3.2m analytical lab at NC facility

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/JK1991)
(Image: iStock/JK1991)
Cambrex Corporation is adding a new $3.2m, 11,000 square foot analytical laboratory to its High Point, NC-based facility.

According to contract development and manufacturing organization (CDMO), the investment​ follows an increasing customer demand for analytical development and validation services to support cGMP products at the clinical stage.

Demand for analytical and process development and manufacturing at early clinical stages is growing as we see the record number of projects in the clinical pipeline​," Brian Swierenga, site director, VP operations, Cambrex High Point told Outsourcing-Pharma.com.

"At the same ​time the complexity of the molecules and the more stringent regulatory requirements has led to a greater proportional growth in demand for analytical resources,​" he added.

Cambrex purchased the 35,000 square foot High Point site from PharmaCore in October 2016, since which time it has invested more than $5m in the site. The most recent investment follows the addition of a fourth reactor suite​ at the facility in May of this year.

Equipment installation at the High Point facility will begin in Q3 2017. Validation and start up is expected in Q4 2017.

As part of the expansion, the company also plans to add twelve new analytical development scientists to its research and development team.

Last month, Cambrex also announced a $24m investment​ to open a new facility to manufacture high potent APIs at its Charles City, Iowa plant.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars